Part
01
of one
Part
01
Blood Culture Incubator and Bottle: Market Share
Key Takeaways
- The 2022 size of the global blood culture tests market is $64.25 billion.
- The ten dominant players in the global blood culture tests market are Becton, Dickinson and Company, bioMérieux SA, Thermo Fisher Scientific, Inc., Copan Group, Cepheid, Inc., Nanosphere Inc. (now Luminex Corporation), IRIDICA (Parent company: Abbott Laboratories), Beckman Coulter, Brucker Corporation, and T2 Biosystems.
- From our calculations, the players with the largest (%) industry market share are Abbott Laboratories (24.35%) Thermo Fisher Scientific, Inc. (12%), Becton, Dickinson and Company (8.13%), and Beckman Coulter (5.76%). These players held about half (50.24%) the share of the industry market size.
Introduction
The research provides the current size of the global blood culture tests market, including the percentage market share of the ten (10) top players in the industry, including Becton Dickinson (BD), Thermo Fisher, Biomerieux, and Copan. Note that the most current market size of the industry (2022) was provided and used for the calculations, since the report is the most recent industry report (published in January 2022) on the blood culture tests market. Also, the study/base year of the research is 2021.
Additionally, we have sourced the revenues of the public companies from their annual report, while we leveraged information from credible and reliable third-party databases such as Dun & Bradstreet, Inc. and Zippia, to provide the revenues of the private companies. Furthermore, we have not provided/used the total company revenue. This is because these companies also generate revenue from other business sectors in addition to their blood culture tests businesses. As a result of which, we have provided the revenue data for their business segment that is linked to blood culture tests. Please note that the above strategy could not be applied for Thermo Fisher Scientific Inc. because culture instruments cut across all sectors of their business, as a result of which, we have provided the revenue for its instruments segment.
Below (in the Triangulation section), you'll find an outline of our calculations to better understand the step-by-step procedure followed to obtain the market share of each top player.
Blood Culture Test: Market Size & Top Players
- According to an industry report by Market Data Forecast, the global blood culture tests market is currently valued at $64.25 billion.
- The market is expected to increase to $73.05 billion by 2027 at a CAGR of 2.6%.
- The period of the forecast is between 2023 and 2027.
- Based on the industry report, the dominant players in the industry include:
Dominant Company Revenue
- The revenue of the top companies is provided below:
- Becton, Dickinson and Company: $5.225 billion.
- bioMérieux SA: 31% of €3,376 million = €1,046.56 million ≈ $1.44 billion (Average exchange rate in 2021: 1.3757 USD)
- Thermo Fisher Scientific, Inc.: $7.753 billion.
- Copan Group: $134.52 million
- Cepheid, Inc.: $538.58 million
- Nanosphere Inc. (now Luminex Corporation): $417.40 million
- IRIDICA (Parent company: Abbott Laboratories): $15.644 billion
- Beckman Coulter: $3.7 billion
- Brucker Corporation: $1.2539 billion
- T2 Biosystems: $5.327 million.
Market Share
- The market share of the dominant players in the global blood culture tests market is calculated as thus:
- Becton, Dickinson and Company: 8.13%
- bioMérieux SA: 2.24%
- Thermo Fisher Scientific, Inc.: 12%
- Copan Group: 0.21%
- Cepheid, Inc.: 0.838%
- Nanosphere Inc. (now Luminex Corporation): 0.65%
- IRIDICA (Parent company: Abbott Laboratories): 24.35%
- Beckman Coulter: 5.76%
- Brucker Corporation: 1.95%
- T2 Biosystems: 0.01%.
Research Strategy
For this research, we have leveraged the most reputable and up-to-date industry report available in the public domain to provide the current (2022) market size for the global blood culture tests market. The 2022 market size was used for our calculation because the report by Market Data Forecast was the most recent (published in January 2022) in the public domain. Additionally, the report considered the impact of the Covid-19 Pandemic on the global blood culture tests market. Also, the study/base year of the research is 2021. Other reports available in the public domain such as Grand View Research and Markets and Markets had dated (2018 and 2019, respectively) base years.
To calculate the market share of the dominant players in the industry, first, we leveraged the annual reports of the public companies to provide their revenue data. Please note that for these public companies, we have not provided/used the total company revenue. This is because these companies also generate revenue from other business sectors in addition to their blood culture tests businesses. As a result, we have provided the revenue data for their business segment linked to blood culture tests. Please note that we did not apply this strategy to Thermo Fisher Scientific Inc. because culture instruments cut across its business sectors. As a result, we have provided the revenue for its instruments segment.
For private companies such as Copan Group, we leveraged information from credible and reliable third-party databases such as Dun & Bradstreet, Inc. and Zippia, to provide their revenue data.
Below, you'll find an outline of our calculations to better understand the step-by-step approach followed to obtain the market share of each top player.
Triangulation
- The 2022 size of the global blood culture tests market is $64.25 billion.
- The market share of the dominant players in the global blood culture tests market is calculated by expressing the revenue of each company as a percentage of the global blood culture tests market ($64.25 billion) = [(revenue of the top player ÷ the global blood culture tests market size) × 100].
- Therefore, the market shares of these companies are calculated as thus:
- Becton, Dickinson and Company: [$5.225 billion ÷ $64.25 billion × 100] = 8.13%
- bioMérieux SA: [$1.44 billion ÷ $64.25 billion × 100] = 2.24%
- Thermo Fisher Scientific, Inc.: [$7.753 ÷ $64.25 billion × 100] = 12%
- Copan Group: [$134.52 million ÷ $64.25 billion × 100] = 0.21%
- Cepheid, Inc.: [$538.58 million ÷ $64.25 billion × 100] = 0.838%
- Nanosphere Inc. (now Luminex Corporation): [$417.40 million ÷ $64.25 billion × 100] = 0.65%
- IRIDICA (Parent company: Abbott Laboratories): [$15.644 billion ÷ $64.25 billion × 100] = 24.35%
- Beckman Coulter: [$3.7 billion ÷ $64.25 billion × 100] = 5.76%
- Brucker Corporation: [$1.2539 billion ÷ $64.25 billion × 100] = 1.95%
- T2 Biosystems: [$5.327 million ÷ $64.25 billion × 100] = 0.01%.